Phase 2 N=48 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
Liposarcoma · Leiomyosarcoma · Fibrosarcoma
Primary: Number of Participants With Overall Response (OR) — 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=29 Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma
Liposarcoma,Myxoid
Primary: Percentage of Participants With Pathological Complete Response (pCR) — 13 percentage of participants
Phase 2 N=52 Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial
Advanced and / or Metastatic Liposarcoma
Primary: Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment — 54.1; 46.2 percentage of participants
Phase 2 N=73 Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Sarcoma, Soft Tissue · Soft Tissue Sarcoma · Undifferentiated Pleomorphic Sarcoma
Primary: Progression-free Survival (PFS) (Arm 1 Only) — 5.48 months
Phase 2 N=25 Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma
Sarcoma
Primary: Number of Patients With Dose Limiting Toxicities. — 0; 1; 0 Participants
Phase 2 N=13 Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery
Liposarcoma
Primary: Confirmed Overall Response Rate Per the RECIST 1.1 Criteria — 0 percentage of patients
Phase 2 N=20 SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma
Metastatic Leiomyosarcoma
Primary: Response Rate (Per RECIST 1.1) — 1 Participants
Phase 2 N=18 Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans
Dermatofibrosarcoma Protuberans
Primary: To Collect Matched Tumor Tissue of Trial Participants With Dermatofibrosarcoma Protuberans Before and After Treatment With Imatinib for Future Use in cDNA Microarray and…
Phase 2 N=37 Sorafenib and Dacarbazine in Soft Tissue Sarcoma
Sarcoma · Synovial Sarcoma · Leiomyosarcoma
Primary: Overall Objective Response — 5; 22; 8 participants
Phase 2 N=80 Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma
Sarcoma
Primary: Best Anatomical Tumor Response — 0; 2; 22; 30 participants
N/A N=2,165 Patterns of Care and Outcomes in METAstatic Soft Tissue SARComa
Sarcoma · Metastases · Chemotherapy
Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient
Phase 2 N=20 Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma
Pleomorphic Rhabdomyosarcoma · Stage IIB Adult Soft Tissue Sarcoma AJCC v7 · Stage III Adult Soft Tissue Sarcoma AJCC v7
Primary: Pathologic Response Rate, Defined as the Percentage of Participants With Greater Than or Equal to 95% Necrosis. — 20 % of participants
Phase 3 N=87 Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
Desmoid Fibromatosis
Primary: Progression-free Survival(PFS) Rate — 7; 22; 42; 13 Participants — p=<0.001
Phase 2 N=12 Alimta Plus Gemcitabine for Advanced Sarcoma
Sarcoma, Soft Tissue
Primary: Tumor Best Response Rate — 0 Participants
Phase 2 N=147 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
Adult Angiosarcoma · Adult Epithelioid Sarcoma · Adult Leiomyosarcoma
Primary: Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST — 1; 0; 0; 0 participants
Phase 2 N=51 S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas
Sarcoma
Primary: Objective Response (Confirmed, Complete and Partial) — 1; 0; 1; 8 participants
Phase 2 N=16 Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation
Metastatic Soft Tissue Sarcoma
Primary: Part 2: Radiologic Progression-free Survival (PFS) — 18.7; 24.1 weeks — p== 0.6562
Phase 2 N=72 PAZOPANIB Efficacy and Tolerance in Desmoids Tumors
Progressive Desmoids Tumors
Primary: Percentage of Patients Remaining Alive and Progression-free at 6 Months as Per RECIST 1.1 After the Day of Randomisation (6-month Non-progression Rate). — 84.8; 45.0…
Phase 2 N=129 Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial
Sarcoma
Primary: Percentage of Participants in Objective Response at 6 Months — 0.0; 0.0; 0.0; 6.7 percentage of participants
Phase 2 N=14 Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma
Adult Synovial Sarcoma · Recurrent Adult Soft Tissue Sarcoma · Stage III Adult Soft Tissue Sarcoma
Primary: Response Rate (CR + PR) Assessed by RECIST 1.1 (Phase II) — 4; 1; 5; 0 participants
Phase 2 N=20 Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide
Soft-tissue Sarcomas
Primary: Phase I: Maximum Tolerated Dose (MTD) of Trabectedin When Administered in Association With CP. — 0.50 mg/m^2
Phase 2 N=42 A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas
Metastatic Sarcoma
Primary: Disease Control Rate — 13; 2; 3 Participants
Phase 2 N=15 Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)
Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor · Metastatic Osteosarcoma · Recurrent Adult Soft Tissue Sarcoma
Primary: Change in Fludeoxyglucose (FDG) Uptake (Maximal Standardized Uptake Value, or SUVmax)
N/A N=48 Assessment of Helical Tomotherapy Radiotherapy (54 Gy) Followed by Surgery in Retro-peritoneal Liposarcoma
Liposarcoma
Primary: Cumulative Incidence Rate of Local Recurrence and Competing Risks (All Patients) — 16.89; 10.42 percentage of participants
Phase 3 N=588 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Adult Alveolar Soft-part Sarcoma · Adult Angiosarcoma · Adult Epithelioid Sarcoma
Primary: Probability for Event Free Survival. — 0.8984; 0.7647; 0.6079; 0.4873 Probability of EFS at 5 years
Phase 3 N=577 A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
Advanced Liposarcoma or Leiomyosarcoma
Primary: Overall Survival (OS) — 13.73; 13.14 Months
Phase 2 N=8 Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall
Soft Tissue Sarcoma
Primary: Number of Dose Limiting Toxicities — 0; 2 DLTs
Phase 2 N=23 Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma
Neoplasms
Primary: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment — 20; 40 Percentage of participants
N/A N=35 Hypofractionated Pre-operative Radiation Therapy for Soft Tissue Sarcomas of the Extremity and Chest-wall
Soft Tissue Sarcoma
Primary: Local Disease Control Assessed by Physical Examination — 0 Participants
Phase 2 N=17 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
Adult Fibrosarcoma · Adult Leiomyosarcoma · Adult Liposarcoma
Primary: Disease Control Rate, Defined as the Number of Patients Who Achieved Complete Response, Partial Response or Stable Disease For a Period of More Than 4 Months. — 0…